Alan Glombicki, MD
Obesity Medicine · Houston, TXNPI 1669467395
Payments from drug & device makers
Across 495 payments — averaging $841.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$162K
- Takeda Pharmaceuticals U.S.A., Inc.$101K
- Gilead$81K
- Sanofi$39K
- Intercept Pharmaceuticals, Inc.$14K
- Janssen Research & Development, LLC$11K
- plus $8K from 21 others
What the payments were for
- Consulting fees$4,7005%
- Speaking & faculty fees$66,89072%
- Travel & lodging$8,97410%
- Food & beverage$12,57613%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 11 | $162,480 |
| Takeda Pharmaceuticals U.S.A., Inc. | 58 | $101,326 |
| Gilead | 161 | $80,714 |
| Sanofi | 4 | $38,925 |
| Intercept Pharmaceuticals, Inc. | 14 | $13,838 |
| Janssen Research & Development, LLC | 5 | $11,348 |
| AbbVie(2 entities) | 75 | $2,656 |
| E.r. Squibb & Sons, L.L.C. | 12 | $1,285 |
| Johnson & Johnson(2 entities) | 31 | $836 |
| Intra-sana Laboratories | 2 | $779 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $503 |
| Bristol Myers Squibb | 40 | $366 |
| Medtronic(2 entities) | 2 | $265 |
| Shionogi Inc | 8 | $201 |
| Merck | 12 | $195 |
| Dova Pharmaceuticals | 10 | $154 |
| Madrigal Pharmaceuticals | 1 | $147 |
| Pfizer | 8 | $147 |
| Celltrion USA Inc. | 2 | $135 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Redhill Biopharma Inc. | 5 | $87 |
| Ironwood Pharmaceuticals, Inc | 3 | $40 |
| Braintree Laboratories, Inc. | 2 | $34 |
| Mirum Pharmaceuticals, Inc. | 1 | $32 |
| Ipsen Biopharmaceuticals, Inc | 1 | $28 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Evoke Pharma, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few obesity medicine providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VemlidyTenofovir Alafenamide | 12 | $17,046 |
| LinzessLinaclotide | 22 | $12,829 |
| Sucralfate | 104 | $5,064 |
| Colesevelam Hcl | 19 | $3,831 |
| Misoprostol | 63 | $3,158 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 32 | $2,045 |
| Ursodiol | 12 | $1,656 |
| Lubiprostone | 14 | $909 |
| Peg3350-Sod Sul-Nacl-Kcl-Asb-CPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 11 | $747 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 29 | $509 |
| Clarithromycin | 12 | $386 |
| Omeprazole | 21 | $221 |
| Metronidazole | 13 | $192 |
| Pantoprazole Sodium | 22 | $166 |
| Metoclopramide Hcl | 12 | $146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadVemlidy | $80,714 | $17,04612 claims |
| AbbVieLinzess | $2,656 | $12,82922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obesity medicine providers in Texason file to place this against a meaningful peer group, so we don't.
Other obesity medicine in Houston
- Sameer MuraliHouston$93K
- Sully DrotarDallas$194K
- Suzanne CudaSan Antonio$40K
- Michael SegerSan Antonio$16K
- Richa MittalFrisco$8K
- Kurt ReyesMcKinney$4K
- Laura MontesMcAllen$1K
- Christina UlbrichDallas$793
- Michele CaveneePlano$363
- Ryan RatliffTyler$332
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.